New combo therapy aims to shrink rectal tumors before surgery

NCT ID NCT07281768

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 5 times

Summary

This phase 2 trial will test whether adding immunotherapy drugs (cemiplimab alone or with fianlimab or REGN7075) to standard chemotherapy (capecitabine and oxaliplatin) can completely eliminate tumors in patients with locally advanced rectal cancer before surgery. The study plans to enroll 66 adults with a specific type of rectal cancer (MSS) who have not had prior treatment. The main goal is to see how many patients have no cancer cells left in their surgical specimen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Capecitabine, Oxaliplatin, Cemiplimab, Fianlimab, REGN7075
What this could lead to
If successful, this could offer a new treatment option that shrinks rectal tumors before surgery, potentially improving outcomes and reducing the need for more aggressive treatments.
What could go wrong
This is an early phase 2 trial with only 66 participants, so results may not apply to everyone. Combining drugs can increase side effects, and the added benefit of the immunotherapy drugs is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.